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Purpose—Guidelines recommend that genetic reports should be clear to non-specialists, 
including patients. We investigated the feasibility of creating reports for cystic fibrosis carrier 
testing through a rapid user-centered design process that built on a previously developed generic 
template. We evaluated the new reports’ communication efficacy and effects on comprehension 
against comparable reports used in current clinical practice. 
Methods—30 participants participated in 3 rounds of interviews. Usability problems were 
identified and rectified in each round. 193 participants participated in an evaluation of the 
resulting reports measuring subjective comprehension, risk probability comprehension, perceived 
communication efficacy, and other factors, as compared with standard reports. 
Results—Participants viewing the user-centered reports rated them as clearer, easier to 
understand, and more effective at communicating key information than standard reports. Both 
groups ended up with equivalent knowledge of risk probabilities, although we observed 
differences in how those probabilities were perceived. 
Conclusions—Our findings demonstrate that by starting with a patient-friendly generic report 
template and modifying it for specific scenarios with a rapid user-centered design process, 
reports can be produced that are more effective at communicating key information. The resulting 
reports are now being implemented into clinical care. 
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Genetic and genomic testing is becoming increasingly widely available due to falling costs of 
testing, new referral pathways, increased integration of such testing into mainstream clinical 
practice, and other initiatives such as the National Health Service (NHS) Long Term Plan and the 
“Improving Outcomes through Personalised Medicine” effort in the United Kingdom1. As access 
to such services expands, non-specialist clinicians are increasingly tasked with explaining the 
results of these tests to patients. In some cases, patients may be faced with the prospect of 
interpreting reports themselves without guidance. For example, patients in some countries can 
obtain copies of their test results directly from testing laboratories2. 
Research suggests that even clinicians have difficulties understanding genetic reports3,4, and 
many researchers have recognized the need for clearer reports in light of variability among 
individuals in numeracy, health literacy, and genetic literacy2,5,6. Guidelines state that reports 
should be clear and comprehensible to non-specialists, and provide some guidance on how to 
achieve this2,7–14. Despite widespread adoption of some guidelines, such as those of the 
American College of Medical Genetics and Genomics (ACMG)7, studies investigating patients’ 
and non-specialists’ satisfaction and perceptions find that existing reports leave substantial room 
for improvement4,15–17. Genomic reports are especially challenging due to lack of 
standardization18,19 and the complexity and uncertainty of the information involved20.  
There have been attempts to make the interpretation of laboratory reports clearer to non-
specialist clinicians16,21–25, but far fewer to make them clearer to patients. In 2014, Haga et al.2 
noted that “only one study has described efforts to develop a patient-friendly pathology report” 
(p. 4). There have since been some efforts to make genetic or genomic test reports more patient-
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friendly2,14,26–30, including in the direct-to-consumer (DTC) industry5,30. However, work of this 
kind still appears rarely outside the DTC space, and there has been little published (or made 
publicly available) about the development of DTC reports. There are therefore few examples to 
guide the design and evaluation of a patient-friendly genetic report. 
In industry, it is common for new products to be developed via a user-centered design31,32 
approach whereby changes are made in an iterative process, taking into account the context in 
which the product will be used, key requirements, and feedback from users. Typically, multiple 
rounds of evaluation are conducted, monitoring metric(s) of interest (e.g. number and severity of 
usability issues, time required for users to accomplish a task, etc.) to assess what changes are 
needed. The iterative process continues until some stopping criterion is reached. 
With rare exceptions25,28, user-centered design is not generally used as a guiding framework in 
the context of non-commercial genetic report development. Our aim was to determine whether 
such a process could be used to efficiently produce genetic report templates suitable for 
implementation. If such reports could be shown to communicate more effectively to laypersons, 
this would suggest a reasonable, cost-efficient approach that could be emulated by others. 
Our approach was to split the design phase into two. In a first stage patients, non-specialist 
clinicians and genetic testing experts participated in the development of a report template for a 
fictional genetic condition. This work (submitted for publication) resulted in a generic template 
that could be adapted to specific use cases. We chose cystic fibrosis (CF) carrier testing as our 
specific use case as primary care physicians were being directed to order CF tests (and hence 
receive and communicate results) in our local healthcare region. There was therefore a need to 
ensure that reports from such testing were clear to non-specialist readers. Our study provides 
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preliminary findings regarding benefits and limits of what can be expected from a design process 
of this kind. 
Materials and Methods 
 
One design feature of the generic template was to accommodate the needs of both genetic 
specialists and non-specialists (including patients) by separating sections containing technical 
information from those in “plain English”. Therefore, our reports had both a “patient-centered” 
page and a “clinician-centered” page, with the second page intended for health professionals. 
Five two-page draft reports were developed representing common scenarios for CF carrier 
testing, where the reasons for referral were: partner heterozygous for p.Phe508del (positive and 
negative), familial p.Phe508del (positive and negative), and family history (unknown variant), 
negative report only. Reasons for referral were stated in simpler language on the patient-centered 
page of each report. Our initial reports were developed on the basis of our previously designed 
generic report template, with input from members of a working group who produced 
recommendations based on a revision of the ACGS general reporting guidelines. This group 
included members of the Regional NHS Clinical Genetics Laboratory in Cambridge, clinical 
geneticists, genetic counsellors, National External Quality Assessment Service members and 
other experts in the reporting of genetic test results.  
User-centered testing can take a formative or summative approach. Formative testing is 
conducted iteratively while a product is still in development, whereas summative testing is done 
once the stopping criterion has been met and the design finalized. Their goals differ accordingly: 
whereas “formative testing focuses on identifying ways of making improvements, summative 
testing focuses on evaluating against a set of criteria”33. All five reports were subject to formative 
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testing, and two were selected for summative testing, namely those having “partner heterozygous 
for p.Phe508del” as the reason for referral (Figures S1-S2; sample patient-centered page in 
Figure 1). Corresponding anonymized “standard” report templates currently in use were obtained 
from Yorkshire and North East Genomic Laboratory Hub Central Laboratory to act as a control 
comparison (Figures S3-S4), with permission. Information that could have been used to identify 
the laboratory the templates came from was fictionalized. Informed consent was obtained from 
all participants. This study received ethical approval from the Cambridge Psychology Research 
Ethics Committee (PRE.2018.077). 
 
User-centered design process 
Interviews. Three rounds of semi-structured interviews were conducted over Skype with a 
convenience sample of 30 volunteers recruited from the Cambridge Rare Disease Network, 
individuals who had participated in previous studies, and researcher contacts. 12, 8, and 10 
volunteers participated in each round, respectively. Volunteers were compensated with Amazon 
vouchers for £10. Interviews included questions pertaining to communication efficacy and 
subjective comprehension (e.g., questions about reports’ appearance, structure, confusing 
language, etc.), objective comprehension, and actionability. Demographic information for 
participants in each round is summarized in Table S1.  
Formative evaluation. The primary goal of the formative evaluation was to identify and address 
the most serious usability problems with the reports, borrowing the definition of Lavery et al.34: 
“an aspect of the system and/or a demand on the user which makes it unpleasant, inefficient, 
onerous or impossible for the user to achieve their goals in typical usage situations.” Given that 
typical goals when receiving a genetic report are to (1) understand the contents and (2) to take 
7 
 
appropriate next steps if necessary (or to advise the patient of appropriate next steps), we treated 
as usability problems issues that caused confusion, left participants with incorrect impressions, 
generated unnecessary anxiety, or decreased the odds that a participant would be able to get the 
assistance they needed to take appropriate next steps. After rounds 2-3, interviewer notes and 
partial transcriptions of participants’ answers to interview questions were reviewed and coded in 
MaxQDA to identify and evaluate the most significant problems, highlight cases of poor 
comprehension, and assess the degree to which the reports met participants’ information needs. 
Full coding and partial transcription from interview recordings were completed post-hoc for 
Round 1, but interviewer notes were reviewed and usability problems were enumerated and 
corrected prior to round 2 nevertheless. Our stop criterion for how many rounds of interviewing 
to conduct was that by the final round, no major usability problems should remain. Major 
usability problems are those for which “the user will probably use or attempt to use the product, 
but will be severely limited in his or her ability to do so”35; we considered these to include issues 
that could leave recipients with a serious misconception. 
Because we ultimately wished to run a summative evaluation focusing on subjective 
comprehension, risk probability comprehension, and communication efficacy, we categorized 
participant answers to questions intended to highlight usability issues that might affect these 
constructs in particular, as well as more exploratory constructs of interest (e.g., actionability, the 
degree to which “consumers of diverse backgrounds and varying levels of health literacy can 
identify what they can do based on the information presented”36). These questions were asked to 
help determine whether there were problems in any of these domains so severe as to constitute a 
major usability problem. 
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Summative evaluation. Interviews were followed by an experiment in which participants were 
given either the new (2-page) user-centered report or a standard (1 page) report currently in 
clinical use (and representative of standard practice). Our approach was to provide participants 
with the entire user-centered report, but to ask questions specific to the first page of the report to 
ensure that the patient-facing page was the one being evaluated. After receiving the participant 
information sheet, a consent form, and background information about cystic fibrosis, study 
participants were presented with a clinical scenario in which a hypothetical John and Jane Doe 
are thinking about starting a family. Neither has cystic fibrosis, but CF runs in Jane’s family and 
she is known to be a carrier, so John’s GP has advised him to have a carrier test to inform the 
couple’s family planning decisions. Participants were then shown a copy of “John’s report”, a 
report filled in with fictional information about Mr. Doe, and asked to read it carefully. The 
report shown was either one of the standard reports described earlier, or one of the new user-
centered reports. The evaluation therefore had a 2x2 factorial between-participants design with 
two levels of design (standard and user-centered) and two levels of test result (positive and 
negative). Afterwards, participants completed a questionnaire collecting outcome measures. On 
every questionnaire page, text stated: “Please answer the following based on what you have 
learned from the first page of the report. To take another look at it, you may click here”; clicking 
brought up the first page of the report. Note that basic background information about cystic 
fibrosis was provided to bring the experimental scenario closer to a typical real-world scenario. 
This was not done within the reports themselves, as in the real world a couple with CF in one 
partner’s family would typically be aware of what CF is, particularly after meeting with a GP 
and being referred for testing. 
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Key outcomes were subjective comprehension, risk probability comprehension, and 
communication efficacy. Subjective comprehension was assessed by asking “How well did you 
understand the information in the first page of the report?” and “How clear is the information on 
the first page of the report?” on a seven-point scale ranging from 1 (“not at all”) to 7 
(“completely”). Risk probability comprehension was assessed by tallying the number of risk 
probability comprehension questions answered correctly out of seven presented, counting 
responses within ±1% of the correct answer as “correct.” An investigator blinded to condition 
converted free-text responses to numbers. Communication efficacy was assessed using a version 
of the 18-item questionnaire developed by Scheuner et al.16, modified so as to be appropriate for 
laypersons rather than clinicians (Table 1). A power analysis suggested 192 participants were 
required to achieve 80% power to detect an effect size f of .25 with intent to test main effects and 
two-way interactions via ANOVA. Alpha was adjusted to .01, two-tailed, permitting us to look 
for differences in the three key outcomes described earlier at an alpha of .05 with adjustment for 
multiple hypothesis testing. Normality of residuals was assessed using the Shapiro-Wilk test (= 
.05). 
ANOVA is fairly robust to violations of normality, but for severe violations nonparametric 
alternatives are sometimes applied. For example, the Mann-Whitney test compares the mean 
ranks of two samples, where the rank of a value is determined by ranking all values from low to 
high regardless of sample. Power analysis indicated that if this were used to compare the user-
centered and standard reports on any of our key dependent variables, 192 participants would 
yield 78% power to detect a medium-sized effect (d = .5, = .01). The Scheirer-Ray-Hare 
extension of the Kruskal Wallis test37 is a nonparametric ANOVA alternative based on ranks 
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rather than means; 192 participants would provide 78% power to detect medium-sized main 
effects (f = .25, = .01). 
48 participants were randomized by the Qualtrics survey distribution software to each 
combination of design (standard and user-centered) and test result (positive and negative), 
excepting positive user-centered, which had 49 due to a glitch with Prolific. “Difficult” risk 
probability comprehension questions always followed “easy” questions, but the order in which 
questions were presented was otherwise counterbalanced by question type (Table 2). Our 
minimum acceptable goal for the evaluation was to outperform the standard template on at least 
one key outcome without being inferior on the other two, although we hoped to outperform it 
significantly on all measures. Tests were two-sided with Bonferroni correction for multiple 
hypothesis testing. Measures of central tendency reported in the Results are means, unless 
otherwise stated. 
A secondary goal was to achieve superiority on at least one measure (without being inferior on 
any measure), out of all measures recorded. This included not only key outcomes, but also five 
exploratory measures: trust, actionability, risk probability interpretation, visibility of result 
summary, and ease of understanding the result summary. Trust was assessed by asking “How 
much do you trust the information in the first page of the report?” on a 7-point scale from 1 (“not 
at all”) to 7 (“completely”), and five questions related to actionability were included (Table 1). 
Two risk probability interpretation questions were included— “Is John a carrier of cystic 
fibrosis?” and “If John and Jane have a child, will the child have cystic fibrosis?”—with 
multiple-choice answers (definitely not, unlikely, likely, and definitely). This provides insight into 
how people understand the numbers, but we had no goal beyond ensuring that viewers of 
positive reports did not conclude that the couple would “definitely” or “definitely not” have a 
11 
 
child with CF, and that viewers of negative reports did not conclude that the couple would 
“likely” or “definitely” have a child with CF. This is because there is no right answer with 
respect to whether a 25% chance of having a child with cystic fibrosis feels “unlikely” or all too 
“likely.” Participants were asked whether they had noticed the result summary (the “Your 
Result” box for the user-centered report, or the analogous “Summary” statement for the standard 
report) and how easy the result was to understand (from 1 “not at all easy” to 7 “very easy”). 
Finally, subjective numeracy38 was collected, as well as demographic information.  
Code availability 
Code and data for primary analyses, as well as additional exploratory analyses not reported here, 




Quantitative summaries of participant responses to questions relating to subjective 
comprehension, risk probability comprehension, communication efficacy, and actionability are 
provided in Figures S5-S9 and Table S3. Answers to these questions suggested adequate 
comprehension of the version 3 reports, at least in our small sample of ten participants (Table 
S3). A summary of changes made after each round of testing is available in Tables S4-S5, and 
qualitative description of usability problems in each round and severity classifications are given 
in Table S6, with nothing rising to the level of a major usability problem by the final round. 
Formative evaluation was therefore stopped at this point and a summative evaluation was 
conducted for the version 3 partner reports. A full analysis of all substantive participant 
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comments is beyond the scope of this paper, but a few examples of how specific usability issues 
led to specific changes are detailed in Table S7.  
 One issue noted during Round 3 was that multiple participants commented that they had 
not noticed the result summary box on their first read-through. This did not rise to the level of a 
usability problem as these participants all read and understood the description of the result in the 
“What This Result Means For You” section, but it was of sufficient concern that visibility of 
result summary was added to the summative evaluation as an exploratory measure. 
Summative evaluation 
193 participants were paid £1.96/person to complete the study via Prolific Academic; 
demographic characteristics appear in Table S2. Due to violations of normality, Mann-Whitney 
U-tests were used rather than ANOVAs, comparing mean ranks between the two conditions.  
Subjective comprehension was higher for the user-centered (UC) reports, whether participants 
were asked about understanding (MUC = 5.74, SDUC = 1.18, Mstandard = 4.94, SDstandard = 1.23, U = 
2896, p < .001, d = .7) or clarity (MUC = 5.78, SDUC = 1.20, Mstandard = 4.65, SDstandard = 1.31, U = 
2322, p < .001, d = .9). No differences were observed in risk probability comprehension (MUC = 
4.95, SDUC = 2.30, Mstandard = 4.94, SDstandard = 2.31, U = 4618, p = .9, d = 0.0), and item-wise 
chi-squared tests revealed that no questions in Table 2 were answered correctly more frequently 
in one condition than the other. Like Scheuner et al.16, we compared the mean total scores on 
communication efficacy, finding higher scores for the user-centered reports (MUC = 3.11, SDUC = 
0.56, Mstandard = 2.41, SDstandard = 0.7, U = 2045, p < .001, d = 1.1). Item-wise analyses found 
significant differences for each item in favor of the user-centered reports, all p < .001 (Table 1). 
Analogous U-tests comparing positive vs negative reports were conducted, none of which found 
significant results.  
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User-centered reports trended slightly higher with respect to trust (MUC = 6.23, SDUC = .99, 
Mstandard = 5.92, SDstandard = 1.12, U = 3874, p = .03, d = .3), non-significant after correction for 
multiple hypothesis testing. They were reliably higher on actionability (MUC = 5.41, SDUC = 
1.20, Mstandard = 4.37, SDstandard = 1.47, U = 2733, p < .001, d = 0.8), with item-wise analyses 
favoring the new reports on every question (Table 1). Surprisingly, 27% reported that they had 
not noticed the result summary in the user-centered reports versus 8% in the standard reports, 
X2(1, N = 193) = 10.1, p = .001. However, estimates of John’s probability of being a carrier 
(Table 2, Question 2) were no different, suggesting that this information was clear even to those 
who missed the summary (positive reports: median 100% both conditions, MUC = .86, SDUC = 
.29, Mstandard = .80, SDstandard = .32, U = 1170, p > .9, d = .2; negative reports: median 1% both 
conditions, MUC = .07, SDUC = .16, Mstandard = .07, SDstandard = .16, U = 1161, p > .9, d = 0.0). The 
user-centered reports’ result summaries were also rated easier to understand, MUC = 6.05, SDUC = 
1.33, Mstandard = 5.00, SDstandard = 1.66, U = 2876, p < .001, d = .7. 
When estimating the probability that the first child would have cystic fibrosis (Table 2, Question 
4), there were no significant differences between levels of design for either positive reports 
(median 25% both conditions; MUC = .31, SDUC = .16, Mstandard = .33, SDstandard = .19, U = 1328, p 
= .2, d = -.2) or negative reports (median 1% both conditions; MUC = .10, SDUC = .17, Mstandard = 
.06, SDstandard = .11, U = 1100, p = .8, d = .3). Nevertheless, responses to the risk interpretation 
questions suggested possible differences in the interpretation of these numbers (Figure 2) for 
those who had been shown the positive reports, with those who saw the user-centered positive 
report more apt to say that a child of two carriers was “unlikely” to have cystic fibrosis than 
those who saw the standard positive report, X2(1, N = 97) = 7.8, p = .005. Overall performance 
with respect to the goals of the evaluation is summarized in Table S8. 
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Despite the violations of normality, 2x2 ANOVAs crossing design with test result as well as the 
Scheirer-Ray-Hare extension of the Kruskal Wallis test were also run on our key dependent 
measures. In both cases the same main effects were found, with no significant interactions. 
Discussion 
 
Our findings suggest that by starting with a patient-friendly generic report template and 
modifying it for a specific genetic test with a rapid user-centered design process, reports can be 
made that laypersons find significantly clearer, easier to understand, and more effective at 
communicating key information, including what they should do next (actionability). The 
improvements in actionability are particularly encouraging, as several interview participants 
noted that it is especially important that patients feel they understand “next steps”, and that they 
feel they have adequate information and support to make follow-up decisions. We also saw 
cautions from the risk comprehension literature39 borne out in our qualitative results (Table 3). 
Although we found no differences in risk probability comprehension, performance was near 
ceiling, with a median of 6 out of 7 questions correct for both the user-centered and standard 
reports. Furthermore, combining user-centered testing with quantitative evaluation led us to 
insights that would have been difficult to achieve without both methods. For example, some 
individuals noted that although they understood their results from reading the text of the report, 
they had missed the summary box titled “Your Result”. Therefore, we added a question 
investigating this to our quantitative evaluation, which confirmed that 27% of participants did 
not remember seeing this box. Thus, even anecdotal evidence from small qualitative studies can 
generate important hypotheses that can then be tested more rigorously. 
One limitation of our formative evaluation was that participants were overwhelmingly female 
(80%) and highly educated (Table S1). Our summative evaluation sample had similar biases 
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(~69% female, ~56% university-educated), among other differences from the UK population 
(Table S2). Although subgroup analysis demonstrated that the benefits of our novel templates 
were thankfully not restricted to women, nor to the highly educated or highly numerate (Table 
S9), our development process could have identified important issues more quickly if we had 
solicited input from a more diverse group of participants from the outset. Given this non-
representative sample and the fact that it was more difficult to see the result summary in our 
report than in the standard report, we have made one additional change to address this, and are 
planning a replication of our summative evaluation with this new report using census-matched 
cross-stratified quota sampling.  
Another drawback is that the use of a hypothetical scenario with our testing group means that our 
results are less likely to generalize than if they had been conducted as part of a clinical study. 
(See Stuckey et al. 201526, Williams et al. 201828 for examples of patient-facing work that does 
not suffer from this limitation.) Furthermore, this study was limited to a single autosomal 
recessive condition. We have planned future research on reports for BRCA1/BRCA2 testing, 
which will investigate whether the benefits of this approach generalize to material that is more 
challenging to communicate.  
Overall, our experience demonstrated that a user-centered approach can be extremely helpful in 
discovering and rectifying usability problems with genetic reports. We hope that this research 
illustrates how rapid user-centered design can be used to develop more comprehensible and 
actionable reports, and that building on templates developed via user-centered design may be 
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Figure 1. Patient-friendly page of user-centered “Positive / Partner p.Phe508del” report. 
Figure 2. Responses given by participants who viewed reports with positive test results to the 
question “If John and Jane have a child, will the child have cystic fibrosis?” When asked to 
produce the numeric probability that the first child would have cystic fibrosis (Table 2, Section 
4), participants who felt it was “likely” that the first child would have cystic fibrosis had mean 
estimates of 34% (SD = 21%) if they had seen the standard report, compared to 31% (SD = 12%) 
if they had seen the user-centered report (no significant difference, U = 473, p = .7). Participants 
who felt it was “unlikely” that the first child would have cystic fibrosis had mean estimates of 
25% (SD = .4%) if they had seen the standard report, compared to 27% (SD = 14%) if they had 
seen the user-centered report (no significant difference, U = 100, p = .4).  
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Table 1. Scores for the standard and user-centered reports.a 
 Standard report  User-centered report  
 Mean SD  Mean SD p-value 
Subjective comprehension, clarity, trust 
(7-point scale) 
      
How well did you understand the information… 4.94 1.23  5.74 1.18 <.001 
How clear is the information…  4.65 1.31  5.78 1.20 <.001 
How much do you trust the information…  5.92 1.12  6.23 0.99 .03 
 
Communication efficacy  
(4-point scale modified from Scheuner et al, 2013) 
      
How satisfied are you with…       
The general format (look and feel) …  2.62 0.90  3.31 0.71 <.001 
The amount of information… 2.83 0.83  3.38 0.73 <.001 
The organization of the information… 2.68 0.88  3.29 0.71 <.001 
How easy is it to…       
Find the test result… 2.67 0.95  3.35 0.78 <.001 
Find information… to help with decision making? 2.42 0.90  3.10 0.78 <.001 
Understand the language used… 2.35 0.88  3.25 0.78 <.001 
Understand the test result presented… 2.53 0.89  3.34 0.76 <.001 
Understand the interpretation of the test result… 2.56 0.90  3.13 0.80 <.001 
How effectively does the first page of the report…       
Communicate the test result? 2.67 0.88  3.38 0.73 <.001 
Communicate what this test result means? 2.47 0.98  3.23 0.67 <.001 
Communicate the patient’s options (i.e., John’s options) 
having received this test result? 
2.16 1.00  2.94 0.79 <.001 
Communicate the availability of information resources for the 
patient (i.e., John)? 
1.98 0.96  2.95 0.86 <.001 
Communicate the availability of information resources for 
health professionals (i.e., John's GP)? 
2.10 0.92  2.87 0.82 <.001 
Inform medical decisions the patient (i.e., John) might have to 
make as a result of this test? 
2.46 0.99  3.01 0.74 <.001 
Help you explain what the test result means to other people? 2.42 0.93  3.00 0.88 <.001 
Help you understand the medical issues relating to the result? 2.27 0.90  2.81 0.89 <.001 
Help you understand the genetic aspects of the result? 2.40 0.93  2.97 0.85 <.001 




      
How clear are you about the next steps that you could take… 4.40 1.60  5.53 1.35 <.001 
Do you feel you would have the necessary information to 
decide what to do next… 
4.26 1.71  5.21 1.52 <.001 
How certain are you about what you would do next… 4.49 1.75  5.62 1.32 <.001 
Do you feel you would have the necessary professional 
support to decide what to do next… 
4.45 1.53  5.47 1.30 <.001 
How ready would you feel to take any next steps… 4.27 1.72  5.21 1.38 <.001 
 
aTo make the table more compact, ellipses (“…”) appearing in communication efficacy questions and subjective 
understanding/clarity/trust questions stand in for the phrase “in the first page of the report” (“of the first page of the 
report,” communication efficacy question 1). Ellipses appearing in actionability questions stand in for the phrase “if 
you had received this report in real life.” 
 
Table 1
Table 2. Measures of participant comprehension of risk probabilities. 
Question ID/type 
and difficulty 
Question Answer format 
Q1/Carrier risk 
(easy) 
What do you think the probability is that John is a 
carrier of cystic fibrosis? You can indicate this 






Please indicate the probability that John is a carrier 
of cystic fibrosis by dragging the slider below. a 
 
Probability slider from “0% chance” 
to “100% chance” 
Q3/Risk to child 
(easy) 
If John and Jane have a child, what do you think the 
probability is that the child will have cystic 
fibrosis? You can indicate this probability as a 
percentage, or in another way if you prefer. 
 
Free text 
Q4/Risk to child 
(easy) 
Please indicate the probability that the child will 
have cystic fibrosis by dragging the slider below. a 
 
Probability slider from “0% chance” 
to “100% chance” 
Q5/Risk to child 
(hard) 
Imagine that there are 1000 couples in exactly the 
same situation as John and Jane: that is to say,     
o one partner is a carrier (like Jane is), and    
o the other partner has had the same test that John 
has had, and received the same result as John 
did. 
 
If each of these 1000 couples have one child, about 
how many of these 1000 children would have cystic 
fibrosis?   
 
If you aren't sure, or if you think there are many 
possibilities, please make your best guess as to the 
most likely number of children to have cystic 
fibrosis, from 0 to 1000. 
 
Free text; single number expected 
Q6/Risk to child 
(hard) 
[As above with “800” in place of “1000”] 
 
 
Free text; single number expected 
Q7/Both risks Which of the following possibilities is more likely? 
o John Doe is a carrier of cystic fibrosis 
o The first child of John and Jane Doe will have 
cystic fibrosis 
Multiple choice: 
 It’s more likely that John Doe is a 
carrier of cystic fibrosis 
 It’s more likely that the first child 
of John and Jane Doe will have 
cystic fibrosis 
 Both possibilities are equally likely 
 Don’t know 
 
 
aThe following text followed in both cases: “If you aren't sure, please make your best guess. If you can't mark 




Table 3. Recommendations and lessons learned. 
Topic Recommendation 
Design Splitting the design process into two phases—one to develop a generic template with 
key sections and information that patients want from the results, and one to populate 
that template with the specific numbers and information for each type of test—may 
provide an efficient way to produce large numbers of report templates for medical test 
results. 
 
 Test with users: recommendations from the literature should not be applied blindly. 
For example, although there are good reasons to present risk figures in multiple 
formats as a general rule, in our case including “1 in 25 (4%)” and “1 in 4 (25%)” in 
close proximity caused confusion. User testing permitted us to address the issue in a 
way that allowed us to continue following the recommendation but also eliminated 
the confusion.  
 
 Focus on recruitment of diverse representative end users throughout the process. We 
benefited from multiple perspectives of different user groups (healthcare providers, 
patients, and members of the public with varying levels of experience of genetic 
testing), and would have benefited from a more concerted effort to recruit participants 
who were more diverse in other ways (e.g. education). 
 
Evaluation Following up on comments from interviews with a larger sample size can be a useful 
way to determine whether an offhand comment (“I don’t know how I missed that!”) is 
indicative of a larger issue (27% of participants indicating that they did not see the 
result summary box). 
 
 Formative and summative evaluation both ought to be applied to important patient-




When using vocabulary that implies a change in risk (e.g. reduce/increase), the risks 
being compared must be clearly described. 
 
For patient-facing materials, “gene changes” is a poor plain-English alternative to 
“variant,” as it sometimes led to misinterpretations (e.g., “What does it mean by no 
cystic fibrosis gene changes detected? Can genes change throughout the life course or 
something? I thought you’re kind of born with it or you're not.”) In our study, 
“alterations” seemed to be reasonably well received and interpreted. 
 
 Prior literature39 has found that a quarter of people incorrectly answer the question 
“Which of the following numbers represents the biggest risk of getting a disease? 1 in 
100, 1 in 1000, or 1 in 10?”, not realizing that a larger number in the denominator 
corresponds to a smaller probability. A quote from one of our participants suggested 
she had a similar misapprehension (“less than 1 in 500 sounds less scary, because then 
you can think, oh, it could be 400 or 200”). When presenting probabilities that are 
intended to be compared with each other, keep denominators constant to decrease the 
chances of misinterpretation, i.e., compare 1 in 1000 to 6 in 1000 rather than 









User-centered “Negative / Partner p.Phe508del” report. 
 
Figure S3 
Standard “Positive / Partner p.Phe508del” report. 
  
Figure S4 
Standard “Negative / Partner p.Phe508del” report. 
Figure S5 
Participant answers to the question “Is the patient given enough guidance about the implications of the result and what actions they could now take?” were coded 
by 3 independent raters (Fleiss’ kappa 0.6) into the categories indicated in the legend. Visualisation on left panel includes all participants, while right panel 






Participant answers to the question “What are your thoughts on the wording of the report and the level of the language used on page 1?” were coded for participant 
approval by 3 independent raters (Fleiss’ kappa 0.7) into the categories indicated in the legend. Visualisation on left panel includes all participants, while right 





Participant answers to the question “What are your thoughts on the wording of the report and the level of the language used on page 1?” were coded for confusion 
by 3 independent raters (Fleiss’ kappa 0.6) into the categories indicated in the legend. Visualisation on left panel includes all participants, while right panel 





Participant answers to the question “Are there any particular words or phrases that are confusing?” were coded by 3 independent raters (Fleiss’ kappa 0.8) into the 





Participant answers to the question “Is there any information that you’d be left wanting to know after reading this report?” were coded by 3 independent raters 






























Density plot of ease of understanding of the result summary. 
 
 
Table S1. Demographics of participants in formative evaluation. 
 Round 1 Round 2 Round 3 
Participants 12 8 10 
Age range 22-51 26-46 19-52 
Gender    
    Male 4 (33%) 1 (12%) 1 (10%) 
    Female 8 (67%) 7 (88%) 9 (90%) 
Education    
    No university 2 (17%) 1 (12%) 3 (30%) 
    Bachelors 4 (33%) 3 (38%) 6 (50%) 
    Post-graduate 6 (50%) 4 (50%) 1 (10%) 
Health professional?    
    Yes 5 (42%) 2 (25%) 1 (10%) 
    No 7 (58%) 6 (75%) 9 (90%) 
Indicated that they 
themselves had CF or 
relative with CF? a 
      
    No 12 (100%) 8 (100%) 10 (100%) 
 
aParticipants were not explicitly asked whether they had CF or had a relative with CF, but were asked whether they 
had experience with cystic fibrosis. 3 participants in Round 1 had cared for patients with CF, 1 indicated having 
known someone with CF, and 1 mentioned learning about it at school. 1 participant in Round 2 mentioned 
encountering CF in a clinical science rotation. 1 participant in Round 3 mentioned encountering CF as part of 
medical studies, and 1 participant mentioned knowing individuals with CF. 
  
Supplementary Tables
Table S2. Demographics of participants in summative evaluation. 
 N % % in UK population, 
where known 
Gender    
   Male 55 (28%) 49% a 
   Female 134 (69%) 51% a 
   Missing 4 (2%)  
Age group    
   18-24 years 54 (28%) 31% 
b
 
   25-34 years 62 (32%) 13% 
b
 
   35-44 years 38 (20%) 14% 
b
 
   45-54 years 27 (14%) 14% 
b
 
   55+ 8 (4%) 28% 
b
 
    Missing 4 (2%)  
Adults in house    
    1 30 (16%) 20% 
c
 
    2 106 (55%) 53% 
c
 
    3 30 (16%) 16% 
c
 
    4+ 27 (14%) 11% 
c
 
Children in house    
    0 30 (16%) As of 2017, 57% of 
people in UK households 
lived in households with 
one or more children 
d
 
    1 106 (55%) 
    2 30 (16%) 
    3 17 (9%) 
    4+ 10 (5%) 
Combined income    
    Less than £10k 20 (10%) As of 2017/18 financial 
year, quintiles of 
disposable UK household 
income were £13k, £22k, 
£29k, £38k, and £69ke 
    £10k to £20k 28 (14%) 
    £21k to £30k 35 (18%) 
    £31k to £40k 26 (14%) 
    £41k to £50k 18 (9%) 
    £51k to £60k 18 (9%) 
    £61k to £70k 15 (8%) 
    £71k to £80k 5 (3%) 
    £81k to £90k 7 (4%) 
    More than £91k 11 (6%) 
    Missing 10 (5%) 
Education    
    GCSE or equivalent (e.g., level 2 NVQ) 22 (11%) Primary/middle school, 
19%; GCSE or A-levels, 




    A-Level or equivalent (e.g., IB or level 3 NVQ) 61 (32%) 
    Bachelors (e.g., BA, Bsc) 81 (42%) 
    Masters (e.g., MA, MSc) 21 (11%) 
    Doctoral (e.g., PhD) 5 (3%) 
    Missing 3 (2%) 
Subjective numeracy (1 to 6)    
Less than or equal to 3 21 (11%) Unknown in UK 
population. In one large 
study stratified to mirror 
the U.S. population, 25th 
percentile was 3.2, 




3.01 to 4 52 (27%) 
4.01 to 5 70 (36%) 
5.01 or greater 50 (26%) 
Do you have any personal experience with cystic 
fibrosis? 
  
    Yes 8 (4%) 
    No 185 (96%) 
 
a Male and female populations: GOV.UK ethnicity facts and figures, 2018. Available at: https://www.ethnicity-facts-
figures.service.gov.uk/uk-population-by-ethnicity/demographics/male-and-female-populations/latest. Accessed June 
18, 2019. 
b Percentages calculated from Age groups: GOV.UK ethnicity facts and figures, 2019. https://www.ethnicity-facts-
figures.service.gov.uk/uk-population-by-ethnicity/demographics/age-groups/latest. Accessed June 18, 2019. 
c Percentage of adults living in N-adult households calculated from CT0774_2011 Census - Age of Household 
Reference Person (HRP) by number of adults in household - national to local authority level. London: Office for 
National Statistics, 2018. Calculation excludes the 165 households in England and Wales with 15+ adults (less than 
.01% of all households). 
https://www.ons.gov.uk/peoplepopulationandcommunity/housing/adhocs/008208ct07742011censusageofhouseholdr
eferencepersonhrpbynumberofadultsinhouseholdnationaltolocalauthoritylevel. Accessed June 18, 2019. 
d Calculated from Families and households. London: Office for National Statistics, 2017. 
https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/families/datasets/familiesandhou
seholdsfamiliesandhouseholds. Accessed June 18, 2019. 
e From Table 2 of The effects of taxes and benefits on household income, disposable income estimate: 2018. London: 
Office for National Statistics, 2019. 
https://www.ons.gov.uk/peoplepopulationandcommunity/personalandhouseholdfinances/incomeandwealth/bulletins/
householddisposableincomeandinequality/yearending2018/relateddata  
f OECD. Table A1.1 - Educational attainment of 25-64 year-olds (2017): Percentage of adults with a given level of 
education as the highest level attained", in The Output of Educational Institutions and the Impact of Learning, 
OECD Publishing, Paris, 2018: 54. https://doi.org/10.1787/eag-2018-table14-en. Following up on methodology 
referenced in table notes, and combining this with UK-specific definitions of ISCED levels 
(http://gpseducation.oecd.org/Content/MapOfEducationSystem/GBR/GBR_2011_EN.pdf) reveals that attainment of 
GCSE or A-levels corresponds to columns 5 and 6. 
g Zikmund-Fisher BJ, Smith DM, Ubel PA, Fagerlin A. Validation of the subjective numeracy scale: Effects of low 
numeracy on comprehension of risk communications and utility elicitations. Medical Decision Making 2007 Sep; 
27(5):663-71. 
  
Table S3. Risk comprehension questions presented in rounds 2 and 3 of interviews. 
Question Correct answer Number answering 
correctly, round 2 
Number answering 
correctly, round 3 
For a random person in the UK 
who has never been tested for CF, 
what are their chances of being a 
carrier? 
 
1 in 25 (4%) 7 of 8 (first answer given) 
8 of 8 (after self-correction) 
10 of 10 (first answer given) 
10 of 10 (after self-correction) 
And what are their chances of not 
being a carrier? 
 
24 in 25 (96%) 7 of 8 (first answer given) 
8 of 8 (after self-correction) 
9 of 10 (first answer given) 
10 of 10 (after self-correction) 
If both you and your partner are 
carriers, what is the chance in 
each pregnancy of having a child 
that has CF? 
 
1 in 4 (25%) 8 of 8 (first answer given) 
8 of 8 (after self-correction) 
9 of 10 (first answer given) 
10 of 10 (after self-correction) 
If you are a carrier and you have a 
child with someone who has 
never been tested, what are the 
chances then that the child will 
have CF? 
 
less than 1 in 100 
(less than 1%) 
5 of 8 (first answer given) 
5 of 8 (after self-correction) 
8 of 10 (first answer given) 
10 of 10 (after self-correction) 
If both you and your partner are 
carriers, what is the chance in 
each pregnancy of having a 
healthy child? 
3 in 4 (75%) 8 of 8 (first answer given) 
8 of 8 (after self-correction) 
7 of 10 (first answer given) 
9 of 10 (after self-correction) 
 
  
Table S4. Summary of main changes to reports made from version 1 to version 2. 
Section Changes 
Reason for Test 
 
 Black to blue 
 Bold 
 Acronym “CF” used 
 
About The Test  Section added to explain inheritance and meaning of “carrier”  
 Acronym “CF” introduced 
 
Results Box  “Result” to “Your Result” – bold 
 “gene changes” to “gene alterations” 
 
What This Result 
Means 
 
 “What This Result Means” to “What This Result Means for You” 
 Explanation of “carrier” removed as covered in About The Test 
 “single altered Cystic Fibrosis gene” to “one copy of your CFTR genes” [positive 
reports] 
 “not a carrier of CF” to “not a known carrier of CF” [positive reports] 
 “gene changes” to “gene alterations” 
 “assuming that you are of Northern European origin and that the family 
relationships stated in the referral are correct” removed [negative reports] 
 General wording and sentence structure changed to improve explanations, grammar 
and flow; key risk figures represented with both “X in Y” and as a percentage 
 Sentence order rearranged to improve comprehension of risk, with some figures 
removed all together and some risk formats altered 
 
Next Steps  Text bold and presented as bullet points (using dashes) 
 “…but if you have questions about it, talk to your doctor” added after “You do not 
need to do anything as a result of this test” 






 “If you don’t have access to the internet, contact the doctor who ordered your test” 
removed 




 Section headings bold 
 Separate line for each point 





 “For Your Records” bold 
 “If there is anything you do not understand, your doctor will help you to interpret 
this information” to “The information on this page is for health professionals. It is 




 Risk of a false positive/negative added 




 “gene change” to “gene variant” 




 Full Interpretation section moved above Test Methodology 
 
 




 Order of patient details changed to reflect usual laboratory use of information i.e. 
name followed by date of birth. (also on p.2) 
 “Copies to” added 
 Details in “Test carried out by” altered to reflect usual laboratory use of 
information: 
 “Name” removed 
 “Date of Test” replaced with “Date received” and “Date Reported” 
 “Signature” replaced with “Authorised by” 
 
About The Test  Heading bold 
 
Results Box  “No Cystic Fibrosis gene alterations detected” to “No common cystic fibrosis gene 
alterations detected” [Negative / Partner p.Phe508del] 
 
What This Result 
Means for You 
 “each pregnancy” made bold [positive reports & Negative / Partner p.Phe508del] 
 “affected with CF” to “have CF” [positive reports & Negative / Partner 
p.Phe508del] 
 “someone who is not a known carrier of CF” to “someone who has not been tested 
for CF” [positive reports] 
 “(some risk remains as your partner may be a carrier but not know)” added [positive 
reports] 
 “No alterations were detected” to “No alterations were detected, so you are not a 
carrier of any of the alterations we tested for” [negative reports] 
 “This may require an additional test” added [Negative / Family history] 
 “This is low, so prenatal testing is not offered” removed [Negative / Partner 
p.Phe508del] 
 Some wording changed to improve explanations, grammar and flow. 
 Some risk figures removed 
 
Next Steps  All text bold 
 Dashes replaced with bullet points 
 “we could do a more accurate test” to “we could investigate further” [Negative / 
Family history] 
 Alternative options for relatives living in/outside of East Anglia moved to page 2 
and replaced with “If your relatives would like to be tested, they should ask their GP 





 Phone number for the Regional Genetics Service added 
 “call” to “phone”  
 “http://” removed from web addresses 
 Note. By request of the Cystic Fibrosis Trust, the website but not the helpline 




 About The Test section moved under, rather than above, Your Result box 
 Dashed lines between sections removed 
 Pattern of pale blue shading altered to aid visual separation of sections (Design 2) 









 “i” in “interpretation” capitalised in heading 
 “assuming that he is of Northern European origin” removed 
 “John Doe’s CF carrier risk could be determined significantly more accurately if 
details of the familial CFTR gene variants were known” to “If the specific familial 
CFTR gene variant were known, we could assess John Doe’s CF carrier risk directly 
with a targeted test” [Negative / Family history] 








Table S6. Usability problems uncovered through user testing. 
Round Severitya Issue 
   
1 4 
 
Population risk presented in a confusing, arguably misleading way which 
implied to some participants that the recipient’s carrier risk had been 
“reduced” from 1 in 25 to 1 in 18 (which was not the case and is not a 
reduction) 
 
 3 Ethnicity/family relationships disclaimer on p. 1 caused consternation 
 3 Basic result (carrier vs. likely noncarrier status) not always understood 
 3 Percentage of CFTR gene variants not covered by the test (15%) confused 
with percentage chance of not being a carrier 
 3 Reference to “gene changes” misinterpreted (“Can genes change throughout 
the lifecourse or something? I thought you're kind of born with it or you're 
not”) 
 
 2 Concern about why there was residual risk of being a carrier on negative 
reports 
 
 2 No phone numbers provided in “More Information and Support” for 
individuals without internet access 
 
 2 Annoyance at imprecision of the “low” risk of being a carrier on negative 
reports 
 
 2 Several participants felt that “You do not need to do anything as a result of 
this test” alone left them hanging, requested more information about who to 
contact with questions 
 
 1 ‘Next Steps’ section did not remind recipient to take this report to future 
appointments with the Clinical Genetics Service 
   
 1 Various cosmetic features made it unnecessarily difficult to visually 
distinguish between different sections and between recommended “next 
steps” 
 




For negative reports, concern about the 15% of UK CFTR gene variants not 
covered by the test that seemed highly disproportionate to risk of being a 
carrier (less than 0.2%); 15% of CFTR gene variants not covered by the test 
potentially still being confused with the risk of carrying a pathogenic variant 
 
 2 Some confusion from unfortunate coincidence of “1 in 25 (4%)” followed by 




Concern that recipients would want a better explanation of exactly why there 
is a 1 in 4 chance that any given child of two carriers will have cystic fibrosis 
 
 2 Participants did not notice heading indicating that page 2 was primarily for 
their clinician and did not need to be read and understood by patients 
 
 2 More clarity requested on why the report cannot be more definitive  
 
 2 Phone number of Regional Genetics Service not provided 
 
 2 Confusion about how to interpret “affected with CF” in context of interviewer 
questions; possibility of confusion since this phrase is used on reports as well 
 
 1 Differentiating people living inside vs. outside East Anglia is confusing, as 
next step for people whose relatives would like to be tested is to discuss with 
GP in either case 
 
 1 Easy to skip over “About the Test” section, as eye is drawn to the result first 
 
 1 Table on p. 2 hard to read without borders 
 
 1 Various requests related to increasing visual clarity (too busy, too many fonts, 
dashed lines not necessary, needs more white space, etc.) 
 
   
3 2 Mentioning that results “can be upsetting and difficult to take in” on negative 
reports confusing 
 
 2 Participants did not notice heading indicating that page 2 was primarily for 
their clinician and did not need to be read and understood by patients 
 
 2 More clarity requested on why the report cannot be more definitive  
 
 2 Confusion about which ‘doctor’ to return to with questions 
 
 2 Some confusion about what CFTR means (though no confusion about the fact 
that it referred to a gene) 
 




“If you plan to have children, CF carrier testing can be offered to your partner 
before any pregnancy” may be more visible if placed in “Next Steps” section, 
arguably a more appropriate place for it, rather than current location 
 
 1 Requests to further increase separation between different sections 
   
 
a
We used a severity rating scale borrowed from Rubin (1994)b, which we adapted to our specific case to make issues 
easier to classify: 
1: “The problem occurs rarely, can be circumvented easily, or is dependent on a standard that is outside the 
product’s boundaries. Could also be a cosmetic problem.” 
2: “The user will be able to use the product, but may have to undertake some moderate effort to get around the 
problem.” We considered this to include wishes for additional information or clarity that could be satisfied by asking 
one’s GP.  
3: “The user will probably use or attempt to use the product, but will be severely limited in his or her ability to do 
so.” We considered this to include issues that could leave recipients with a serious misconception.  
4: “The user is not able to or will not want to use a particular part of the product because of the way that the product 
has been designed and implemented.” We had one case of this in Round 1, resulting from an issue that would have 
been a (3) if not for one user’s strong negative emotional reaction. 
 
bRubin J. Handbook of usability testing: how to plan, design and conduct effective tests. New York, NY: John Wiley 
& Sons, 1994.   
Table S7. Examples of how specific usability problems were addressed. 
 
Issue Response 
Confusion over whether CF “gene changes” – a phrase 
introduced as a plain-English alternative to “pathogenic variants” 
– could occur in the future (“What does it mean by no cystic 
fibrosis gene changes detected? Can genes change throughout the 
life course or something? I thought you’re kind of born with it or 
you're not.”) 
“Alterations” employed as plain-English 
alternative to “changes” or “variants” 
 
Information about the 85% of pathogenic variants covered by the 
panel was confused with the risk of being a carrier (e.g. “There’s 




Restated for clarification; ultimately 
removed 85% statistic from patient-facing 
page altogether as the restatement did not 
solve the issue 
Confusion around the juxtaposition of a sentence stating that the 
risk is now known to be lower than their a priori risk (“The fact 
that we did not detect any changes reduces the chance that you 
carry a CF gene change slightly, to 1 in 18”) and an unrelated 
sentence earlier in the report stating the population risk (“In the 
UK population, around 1 in 25 people are carriers of CF”); this 
was interpreted as a risk of 1 in 25 that had been “reduced” to a 
(greater) risk of 1 in 18. 
Sentences rephrased for clarity. The further 
confusion caused by comparing two risks of 
differing denominators (given that the risk 
with the larger denominator was 
misinterpreted as the higher risk in at least 
one case) was addressed by expressing 
carrier risk as a percentage and as “1 in 18,” 
and the a priori risk as a percentage only 
 
Confusion from unfortunate coincidence of “1 in 25 (4%)” 
followed by “1 in 4 (25%)” in immediately following sentence 
Moved the statement about the 4% of 
individuals who are carriers of CF in the UK 
population to a more contextually 




Table S8. Performance of user-centered reports vs. standard reports, summarized. The user-centered report is 
deemed “better” or “worse” when differences are statistically significant (adjusted = .01). All values other than 
percentages are means. 
  
 Performance of user-centered report 
(user-centered report vs. standard report) 
Key objectives  
Risk probability comprehension scores Equivalent 
(4.95 vs. 4.94) 
Subjective comprehension scores   
Subjective understanding Better 
(5.74 vs. 4.94) 
 
Subjective clarity Better 
(5.78 vs. 4.65) 
 
Communication efficacy scores Better 
(3.11 vs. 2.41) 
Exploratory objectives  
Trust scores Equivalent 
(6.23 vs. 5.92) 
 
Actionability scores Better 
(5.41 vs. 4.37) 
 
Risk probability interpretation  
(What % of interpretations were clearly wronga?) 
Equivalent 
(5% vs. 7% wrong) 
 
Visibility of result summary 
(What % of the time was result summary noticed?)  
Worse 
(73% vs. 92%) 
Ease of understanding result summary scores Better 
(6.05 vs. 5.00) 
Primary goal: Key objectives  
Better performance on at least one;  
worse performance on none 
 
Met 
Secondary goal: All objectives  
Better performance on at least one;  




a “Clearly wrong” interpretations were beliefs that the first child of a couple receiving a positive report would “definitely” or 
“definitely not” have CF, and beliefs that the first child of a couple receiving a negative report would “definitely” or “likely” 
have CF. 
 Table S9. Subgroup analyses (Mann-Whitney U-tests). 
 Standard report  User-centered 
report 
   
 Mean SD  Mean SD U Cohen’s 
d 
p-value 
Participants who did not attend university 
(n = 83) 
 
        
Risk probability comprehension 4.61 2.43  4.29 2.53 872 -.13 .72 
Subjective understanding  4.78 1.26  5.50 1.26 563 .57 .01 
Subjective clarity 4.61 1.32  5.91 1.26 382 1.0 <.001 
Communication efficacy 2.43 0.65  3.10 0.57 354 1.1 <.001 
Actionability 4.41 1.33  5.23 1.29 554 .62 .01 
Ease of understanding result summary  4.92 1.63  5.97 1.34 514 .69 .002 
 
Participants with low subjective numeracya 
(n = 80)  
 
        
Risk probability comprehension 3.90 2.36  3.62 2.46 853 -.12 .60 
Subjective comprehension  4.63 1.16  5.28 1.36 538 .52 .01 
Subjective clarity 4.46 1.14  5.49 1.41 411 .80 <.001 
Communication efficacy 2.29 0.69  2.99 0.69 368 1.0 <.001 
Actionability 3.97 1.35  5.17 1.25 420 .93 <.001 
Ease of understanding result summary  4.68 1.57  5.79 1.47 470 .73 <.001 
Men (n = 55)         
Risk probability comprehension 4.63 2.40  5.29 2.23 304 .28 .20 
Subjective comprehension  4.48 1.34  5.96 1.04 141 1.2 <.001 
Subjective clarity 4.26 1.40  5.96 1.04 122 1.4 <.001 
Communication efficacy 2.38 0.64  3.14 0.51 132 1.3 <.001 
Actionability 4.28 1.40  5.56 1.18 184 .99 .001 
Ease of understanding result summary  4.81 1.84  6.43 1.03 184 1.1 <.001 
Women (n = 134)         
Risk probability comprehension 5.00 2.28  4.87 2.34 2316 -.06 .75 
Subjective comprehension  5.15 1.13  5.66 1.23 1645 .43 .006 
Subjective clarity 4.81 1.27  5.72 1.25 1282 .72 <.001 
Communication efficacy 2.43 0.73  3.13 0.56 1010 1.08 <.001 
Actionability 4.42 1.51  5.35 1.23 1412 .67 <.001 
Ease of understanding result summary  5.01 1.58  5.96 1.39 1420 .63 <.001 
 
a Defined as falling below the 50th percentile of Zikmund-Fisher et al.’s nationally representative sample of U.S. 
participants. Zikmund-Fisher BJ, Smith DM, Ubel PA, Fagerlin A. Validation of the subjective numeracy scale: 
Effects of low numeracy on comprehension of risk communications and utility elicitations. Medical Decision 
Making 2007 Sep; 27(5):663-71. In our data, subjective numeracy was only mildly correlated with risk probability 
comprehension (r = .4) and had significant but even weaker correlations with other variables. 
 
